Status | Study |
Enrolling by invitation |
Study Name: The Impact of Red Cell Age on Product Utilization in the Chronically Transfused Outpatient Population Condition: Bone Marrow Failure Syndrome Date: 2015-03-05 Interventions: Other: Fresh Human Red Blood Cells |
Enrolling by invitation |
Study Name: Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation Condition: Hematological Malignancy Bone Marrow Failure Syndrome Date: 2012-12-06 Interventions: Drug: Eltrombopag From day +1, start eltrombopag 100 mg/d. |
Completed |
Study Name: Multicenter Retrospective Analysis About the Clinical Characteristics of Korean Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Condition: Hemoglobinuria, Paroxysmal Date: 2010-10-18 |
Active, not recruiting |
Study Name: Peripheral Blood Stem Cell Transplantation Using the CliniMACS Device Condition: Malignant Diseases (ie, Leukemia, MDS, Lymphoma) Non-malignant Diseases (ie, Bone Marrow Fai Date: 2010-02-17 Interventions: Device: CliniMACS (CD+3, CD+19 depletion) |
Completed |
Study Name: Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent PNH Subjects Condition: Hemoglobinuria, Paroxysmal Date: 2009-03-23 Interventions: Drug: Eculizumab Other Name: Soliris |
Completed |
Study Name: The Molecular Biology of Paroxysmal Nocturnal Hemoglobinuria (PNH) Condition: Hemoglobinuria, Paroxysmal Date: 2008-07-23 |
Completed |
Study Name: Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors Condition: Hematologic Neoplasms Anemia, Aplastic Date: 2008-02-08 Interventions: Other: haploidentical allogeneic PBSC transp Days -5 and - |
Approved for marketing |
Study Name: The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol Condition: Hemoglobinuria, Paroxysmal Date: 2007-02-20 Interventions: Drug: eculizumab 600mg IV every week and 900mg IV every 2 weeks |
Completed |
Study Name: Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Condition: Paroxysmal Hemoglobinuria, Nocturnal Date: 2005-07-20 Interventions: Drug: eculizumab 600 mg intrav |
Completed |
Study Name: Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab Condition: Hemoglobinuria, Paroxysmal Date: 2005-07-19 Interventions: Drug: eculizumab |